Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome

Ugur K., Erman F., Turkoglu S., Aydin Y., Aksoy A., Lale A., ...Daha Fazla

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.26, sa.6, ss.2124-2133, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.26355/eurrev_202203_28360
  • Dergi Adı: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2124-2133
  • Anahtar Kelimeler: Asprosin, Visfatin, Subfatin, Obesity, Metabolic syndrome, METEORIN-LIKE METRNL
  • Ankara Üniversitesi Adresli: Evet

Özet

OBJECTIVE: Metabolic syndrome (MetS) and obesity are important public health problems associated with adipose tissue mass. Asprosin, visfatin, and subfatin are new members of which fate in MetS and obesity has not been fully revealed yet. Thus, this study was to investigate the association between asprosin, visfatin, subfatin. and biochemical values, demographic data, and body composition measurement values in MetS patients with and without obesity.